CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn's Disease.

Lukasz KwapiszDavid H BruiningAkitoshi InoueYong S LeePhillip K EdwardsDavid R HolmesRickey E CarterJenifer SiegelmanJoel G Fletcher

Published in: Crohn's & colitis 360 (2022)

Most patients on vedolizumab for over 12 months demonstrated response or stable SB disease when using objective cross-sectional radiologic imaging criteria using CTE/MRE.

Keyphrases

small bowel
end stage renal disease
cross sectional
newly diagnosed
ejection fraction
chronic kidney disease
ulcerative colitis
contrast enhanced
computed tomography
high resolution
peritoneal dialysis
magnetic resonance
prognostic factors
mass spectrometry
dual energy
patient reported
fluorescence imaging